RIVASA 81 MG EC TABLET (DELAYED-RELEASE)

País: Canadà

Idioma: anglès

Font: Health Canada

ingredients actius:

ACETYLSALICYLIC ACID

Disponible des:

LABORATOIRE RIVA INC.

Codi ATC:

B01AC06

Designació comuna internacional (DCI):

ACETYLSALICYLIC ACID

Dosis:

81MG

formulario farmacéutico:

TABLET (DELAYED-RELEASE)

Composición:

ACETYLSALICYLIC ACID 81MG

Vía de administración:

ORAL

Unidades en paquete:

1000

tipo de receta:

OTC

Área terapéutica:

SALICYLATES

Resumen del producto:

Active ingredient group (AIG) number: 0101169013; AHFS:

Estat d'Autorització:

APPROVED

Data d'autorització:

2014-02-17

Fitxa tècnica

_RIVASA 81 MG EC - Product Monograph _
_ _
_Page 1 of 44 _
PRODUCT MONOGRAPH
RIVASA 81 MG EC
Acetylsalicylic
Acid Delayed Release Tablets
81 mg
USP
Platelet aggregation inhibitor
LABORATOIRE RIVA INC.
660 Boul. Industriel
Blainville,
Quebec
J7C 3V4
www.labriva.com
Date of Preparation:
February 17, 2014
Date of Revision:
September 14, 2022
Control Number: 266709
_RIVASA 81 MG EC - Product Monograph _
_ _
_Page 2 of 44 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................... 3
INDICATIONS AND CLINICAL USE
........................................................................
3
CONTRAINDICATIONS
............................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................
4
ADVERSE
REACTIONS.............................................................................................
6
DRUG INTERACTIONS
.............................................................................................
7
DOSAGE AND ADMINISTRATION
..........................................................................
9
OVERDOSAGE
.........................................................................................................10
ACTION AND CLINICAL
PHARMACOLOGY.........................................................11
STORAGE AND STABILITY
....................................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
..........................................12
PART II: SCIENTIFIC INFORMATION
..........................................................................
13
PHARMACEUTICAL INFORMATION
.....................................................................13
CLINICAL TRIALS
...................................................................................................14
DETAILED
PHARMACOLOGY.........